 Home > Active Ingredient News > Study of Nervous System > Nat Aging: Real-world evidence supports the use of bumetanide in the treatment of APOE4-related Alzheimer's disease

Nat Aging: Real-world evidence supports the use of bumetanide in the treatment of APOE4-related Alzheimer's disease

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

rna

tf 1 cells

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Alzheimer's disease is the main cause of dementia worldwide, and there is currently no effective treatment
.

The obvious genetic, pathological, and clinical heterogeneity among AD patients has brought challenges to traditional drug development.

APOE4 genotype is the largest genetic risk factor for late-onset AD.
Compared with APOE3 genotype, heterozygous carriers (approximately 25% of the population) are 3-4 times more likely to develop AD, and homozygous carriers (approximately 2%) risk is 12-14 times
.

Data show that APOE3 and APOE4 play different roles in the pathogenesis of AD, and AD patients and different APOE genotypes respond differently to drug treatment

Precise

Recently, researchers conducted computational drug reuse screening to find drugs for the treatment of lipoprotein E4 (APOE4)-related AD
.

The researchers first established APOE genotype-dependent AD transcriptome characteristics by analyzing public human brain databases

Computational drug reuse screening Computational drug reuse screening

In two independent EHR databases, bumetanide exposure was associated with a significant reduction in the prevalence of AD in individuals over 65 years of age
.

In two independent EHR databases, bumetanide exposure was associated with a significant reduction in the prevalence of AD in individuals over 65 years of age

Bumetanide was determined to be the top drug for the treatment of APOE4-related AD.

In humans, bumetanide exposure is associated with a significant reduction in the prevalence of AD in individuals over 65 years old in two electronic health record databases, indicating the effectiveness of bumetanide in preventing AD.

Original source:

Alice Taubes et al.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Quality Pregabalin 99% powder 148553-50-8 -Shaanxi Dideu Medichem Co.Ltd

CAS No.: 148553-50-8

Chemical Grade

$1/KG FOB

Pregabalin (CNS)

CAS No.: 148553-50-8

Pharmacy Grade

$1/KG FOB

Primidone CAS125-33-7

CAS No.: 125-33-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.